September 11, 2025

aimed analytics secures six-digit first funding and acquires ValueData GmbH

aimed analytics secures six-digit first funding and acquires ValueData GmbH

aimed analytics GmbH has successfully closed its first funding round, raising a six-digit investment. At the same time, the company has completed the acquisition of ValueData GmbH, further strengthening its position as a pioneer in AI-driven biomedical data analytics.

“Our mission is clear: to shape the future of medicine through the power of data analytics. The successful close of this round is a strong validation of our vision and our team’s work.”
Dr. Patrick Günther, CEO of aimed analytics

The investors of this round include proMetis Consulting GmbH, led by Dr. Guido Kemper, and Pi-Holding GmbH. Both partners contribute not only capital but also valuable expertise and strong networks to the company.

With the funding and the integration of ValueData GmbH, aimed analytics aims to accelerate the development of its self-service platform for omics data. The platform allows researchers to analyze complex datasets from genomics, transcriptomics, and epigenomics using natural language – enabling faster, clearer decision-making in drug discovery and biomedical research.

Beyond product development, aimed analytics will expand collaborations with partners in pharma and academia and strengthen its team.

Our latest News

discover more
PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor

PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor

Researchers and physicians at the Hopp Children’s Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases. The individual compassionate-use treatment has now been […]

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m. Eastern Time (ET) to discuss […]

Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies (COS) at Heidelberg University have launched a new research project investigating so-called dipeptides. Some of these naturally occurring protein building blocks are able to neutralize toxic metabolic by-products and may therefore help protect against vascular and kidney damage, particularly […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp